April 12, 2019Open Access

A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma

Key Points

Key points are not available for this paper at this time.

Abstract

Pegylated liposomal doxorubicin in combination with bevacizumab has activity in advanced Kaposi sarcoma, but it is unclear whether the combination yields better outcomes than liposomal doxorubicin used alone.

Bookmark

View Full Paper

Cite This Study

Ramaswami et al. (Fri,) studied this question.

synapsesocial.com/papers/69dbdcfb7d378569a9836703 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-18-3528

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee.1989 · 480 citations
2Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.1996 · 439 citations
3Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin’s lymphoma2005 · 53 citations
4Kaposiʼs sarcoma-associated herpesvirus infection prior to onset of Kaposiʼs sarcoma1996 · 334 citations
5The Effects of Standard Anthracycline-Based Chemotherapy on Soluble ICAM-1 and Vascular Endothelial Growth Factor Levels in Breast Cancer2004 · 75 citations

Bookmark

View Full Paper